IP Verse

Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices

PatentPatent Analysis

EP3300721

NOVO NORDISK
Application Number
EP17196501A
Filing Date
Nov 18, 2004
Status
Patent Maintained As Amended
Dec 6, 2024
Grant Date
Jan 8, 2025
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2729202B2
EP3897582B1
EP4054620B1

Bibliography

The patent EP3300721B2 was granted to Novo Nordisk on Jan 8, 2025 following the initial filing on Nov 18, 2004 under the application number EP17196501A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKDec 6, 2019ADMISSIBLE
HOFFMANN EITLEDec 6, 2019ADMISSIBLE
DR REDDYS LABORATORIESDec 5, 2019ADMISSIBLE
TEVA PHARMACEUTICALSDec 4, 2019ADMISSIBLE
GALENICUM HEALTH SLUDec 4, 2019DEEMED NOT TO HAVE BEEN FILED

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents